8 - 10 November 2018
Madrid, Spain

Sponsorship and Exhibition

Satellite Symposia


Thursday, 8 November 2018


Satellite Symposium Sanofi-Genzyme and RegeneronSAGZ Regeneron Logo 600px
Type 2 Inflammation in Severe Asthma: Clinical and Therapeutic Implications

18:15 – 19:15
Room: Zaragoza I & II
Chair: Santiago Quirce, Spain
•    Welcome and Introductions.  Santiago Quirce, Spain
•    Defining Severe Asthma.  Zuzana Diamant, The Netherlands
•    Type 2 Asthma: What Is it and What Mediators Drive It?  Santiago Quirce, Spain
•    Interactive Session: Identifying Type 2 Asthma in Clinical Practice.  G. Walter Canonica, Italy
•    Closing Remarks and Panel Q&A.  Santiago Quirce, Spain


Friday, 9 November 2018

Satellite Symposium Novartis

New approaches in severe allergic asthma


13:15 – 14:15
Room: Zaragoza I & II
Chair: Ignacio Dávila, Spain
•    Defining the severe allergic asthma patient candidate to biologics.  Santiago Quirce, Spain
•    Component resolved diagnosis in severe allergic asthma.  Olga Luengo, Spain


Satellite Symposium ALK
Relevant outcomes in allergic asthma
 
18:00 – 19:00
Room: Zaragoza I & II
Chair: Eike Wüstenberg, Germany
•    Early identification of asthma deterioration for modifying or preventing severe exacerbations. A clinical trial perspective.  Göran Eriksson, Sweden
•    Can we influence the natural course of asthma in routine care?  Eike Wüstenberg, Germany


Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel